|Articles|April 14, 2023

Pharma USA 2023: Digital Therapeutics and Pharma

Using prescription digital therapeutics can lead to better outcomes for patients, making them a win-win for pharma and patients.

Tracey Dodenhoff, CEO of Medly Therapeutics, discusses her company's heart failure app and why pharma should consider prescription digital therapeutics among their offerings.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related Content

Rohit Tripathi

Who Pays for Tariff Driven Input Cost Increases?

ByNicholas Jacobus,Rohit Tripathi

August 18th 2026

Rohit Tripathi

What Does the Operational Reality of Reshoring Actually Look Like?

ByNicholas Jacobus,Rohit Tripathi

August 17th 2026

2026 Pharm Exec Top 50 Companies

ByMichael Christel

August 14th 2026

From Value Imperative to Operating Reality: Rethinking Trust in Pharma

ByMorten Nielsen,Saule Serikova,Susan M. Snyder

August 14th 2026

Pharma’s New Growth Equation: Smarter Deals, Stronger Science, Rising Costs

ByMichael Christel,Glenn Hunzinger

August 14th 2026

Trending on PharmExec

2026 Pharm Exec Top 50 Companies

M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration with Eli Lilly, Chugai and GSK Enter License Agreement for AID351

Who Pays for Tariff Driven Input Cost Increases?

Pharma’s New Growth Equation: Smarter Deals, Stronger Science, Rising Costs

Bearing the Brunt of IRA-Driven Formulary Pressure: Q&A with Sybil Mead